Other Events ·
On June 25, 2026, Heron Therapeutics received notice from Nasdaq that it failed to meet the minimum $1.00 bid price…
HRTXHeron Therapeutics, Inc.
On June 25, 2026, Heron Therapeutics received notice from Nasdaq that it failed to meet the minimum $1.00 bid price requirement for continued listing, as the closing price remained below this threshold from May 12, 2026, to June 24, 2026. The company has until December 22, 2026, to regain compliance, which requires a closing bid price of at least $1.00 for ten consecutive business days. If compliance is not achieved, the company may seek an additional 180-day extension, potentially through a reverse stock split. The company operates in the biotechnology industry and develops and commercializes pharmaceutical products.